Table 2.
Treatment characteristics
| Treatment | Premenopausal (n = 251) | Postmenopausal (n = 478) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Resection of primary tumour | ||||
| Breast-conserving (incl. follow-up resection) | 173 | 68.9 | 332 | 69.5 |
| Non-breast conserving (mastectomy/ablatio mammae) | 56 | 22.3 | 114 | 23.8 |
| Unknown | 22 | 8.8 | 32 | 6.7 |
| Radiotherapy | ||||
| Yes | 205 | 81.7 | 392 | 82.0 |
| No | 46 | 18.3 | 86 | 18.0 |
| Therapy setting at enrolment | ||||
| Neoadjuvant | 72 | 28.7 | 79 | 16.5 |
| Adjuvant | 179 | 71.3 | 399 | 83.5 |
| Chemotherapy | ||||
| Yes | 242 | 96.4 | 432 | 90.4 |
| No | 9 | 3.6 | 46 | 9.6 |
| Chemotherapy regimen | ||||
| E/A + C + P | 70 | 27.9 | 105 | 22.0 |
| E/A + C + D | 46 | 18.3 | 67 | 14.0 |
| F + E/A + C + D | 40 | 15.9 | 66 | 13.8 |
| F + E/A + C | 22 | 8.8 | 46 | 9.6 |
| Others | 64 | 25.5 | 148 | 31.0 |
| Treatment | Premenopausal, HR-positive (n = 199) | Postmenopausal, HR-positive (n = 354) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Endocrine therapy | ||||
| Yes | 166 | 83.4 | 296 | 83.6 |
| No | 33 | 16.6 | 58 | 16.4 |
| Endocrine therapy regimen | ||||
| Aromatase inhibitors (AI) ± GnRH | 12 | 6.0 | 149 | 42.1 |
| Oestrogen-receptor antagonist | 132 | 66.3 | 88 | 24.9 |
| Switch ER-antagonist/AI | 22 | 11.1 | 55 | 15.5 |
| Others | – | – | 4 | 1.1 |
AI aromatase inhibitor, C cyclophosphamide, D docetaxel, E/A epirubicin/doxorubicin, ER-antagonist oestrogen-receptor antagonist, F fluorouracil, GnRH gonadotropin-releasing hormone, P paclitaxel